Related Experiment Video

Updated: Jun 18, 2026

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

Lessons in hypertension from new clinical trials

Shawna D Nesbitt1

  • 1University of Texas Southwestern Medical Center, Dallas, TX 75390-8586, USA. shawna.nesbitt@utsouthwestern.edu

Postgraduate Medicine
|November 27, 2009
PubMed

Insights

Hypertension often coexists with obesity and diabetes, yet remains undertreated. Early organ damage can occur even at high-normal blood pressure, highlighting the need for comprehensive risk assessment and timely intervention.

Area of Science:

  • Cardiology
  • Epidemiology
  • Nephrology

Background:

  • Hypertension frequently coexists with other cardiovascular risk factors like obesity and diabetes.
  • A significant proportion of hypertension cases remain undertreated in clinical practice.
  • Early organ damage may occur at blood pressure levels previously considered normal, especially in patients with multiple risk factors.

Purpose of the Study:

  • To summarize key findings from recent epidemiologic and clinical studies on hypertension.
  • To emphasize the importance of evaluating global cardiovascular risk.
  • To discuss the role of renin-angiotensin system blockers in managing hypertension with comorbidities.

Main Methods:

  • Review of recent epidemiologic and clinical studies.
  • Analysis of current treatment guidelines and clinical trial data.
  • Focus on patient populations with hypertension, obesity, diabetes, and chronic kidney disease.

Main Results:

  • Hypertension is often associated with other cardiovascular risk factors.
  • Hypertension is frequently undertreated.
  • Early organ damage can manifest at high-normal blood pressure in at-risk individuals.
  • Renin-angiotensin system blockers show efficacy in patients with type 2 diabetes and chronic kidney disease.

Conclusions:

  • A global risk assessment approach is crucial for identifying individuals who will benefit most from antihypertensive therapy.
  • Current US treatment guidelines are evolving to incorporate comprehensive risk evaluation.
  • Pharmacologic agents like renin-angiotensin system blockers are valuable for managing complex hypertension cases involving diabetes and kidney disease.

Related Concept Videos

Hypertension III: Clinical Manifestations and Diagnostic Studies01:30

Hypertension III: Clinical Manifestations and Diagnostic Studies

Hypertension is asymptomatic and also referred to as the "silent killer" until it progresses to a severe stage or causes target organ disease. Patients may experience symptoms stemming from the strain on blood vessels and tissues in various organs or the heart's increased workload.Physical exams might show no abnormalities other than high blood pressure. Signs of vascular damage, when present, correspond to the organs supplied by the affected vessels, leading to target organ damage. For...
Hypertension V: Nursing Management01:23

Hypertension V: Nursing Management

The nursing management of hypertension involves accurately assessing symptoms, making a comprehensive nursing diagnosis, collaborating with patients to set goals, and implementing targeted interventions to mitigate the condition's impact and improve patient well-being.Comprehensive AssessmentThe initial step in nursing care for hypertension involves a thorough patient assessment. It includes evaluating symptoms such as headaches, dizziness, blurred vision, and previous hypertension episodes.
Hypertension IV: Drug Therapy and Lifestyle Modifications01:28

Hypertension IV: Drug Therapy and Lifestyle Modifications

Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...
Hypertension II: Pathophysiology01:29

Hypertension II: Pathophysiology

Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
Hypertension I: Introduction01:28

Hypertension I: Introduction

Hypertension is a widespread, long-term medical condition where blood pressure in the arteries remains elevated. It is characterized by systolic blood pressure readings of 130 mm Hg or above or diastolic blood pressure (DBP) readings of 80 mm Hg or higher. Unmanaged hypertension poses significant health risks, making the distinction between primary (or essential) hypertension and secondary hypertension crucial, as their management and implications vary.Primary HypertensionPrimary hypertension,...
Hypertension and Regulation of Blood Pressure01:18

Hypertension and Regulation of Blood Pressure

Hypertension, the most common cardiovascular disease, is diagnosed through repeated measurements of elevated blood pressure. Its risks, including damage to the kidney, heart, and brain, are directly proportional to blood pressure levels. Starting from 115/75 mm Hg, the risk of cardiovascular disease doubles with each increment of 20/10 mm Hg. The diagnosis relies on blood pressure measurements, not on patient symptoms, as hypertension is often asymptomatic until end-organ damage is imminent or...